Rate Control Self-adjustment in Patients With Permanent or Persistent Atrial Fibrillation Using Device Home Monitoring
Atrial Fibrillation, Persistent
About this trial
This is an interventional supportive care trial for Atrial Fibrillation, Persistent focused on measuring Atrial fibrillation, Patient empowerment, Personalized medicine, Rate control
Eligibility Criteria
Inclusion Criteria:
- patients with persistent or permanent atrial fibrillation, on rate control medication stable for at least 6 months
- patients with a Biotronik pacemaker connected to HM system
Exclusion Criteria:
- patients with heart failure in need of maximum beta blocker titration
- patients with other indications that would prevent medication adjustment
Sites / Locations
- CHUS Fleurimont
Arms of the Study
Arm 1
Experimental
Participants in gradual self-adjustment rate control medication
Patients receive a weekly simplified version of the information transmitted by the HM system. In the first 3 months, using that information, the physician changes or not the rate control medication posology (i.e. if the mean heart rate is 60bpm, betablocker dose is cut to half, and another heart rate evaluation is done a week later, and if heart rate is now 120bpm the dose is increased to a 3/4 of the initial dose, and so on). After those three initial months where physician guide titration, the patient is allowed to make self-adjustment of their medication accordingly to the information received (i.e. increasing or decreasing their rate control medication depending on heart rates and activity hours per day.